Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.

The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire ...

The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...

Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.

FDA's Center for Drug Evaluation and Research director, Patrizia Cavazzoni, MD, to step down in mid-January. Other top leaders also leaving FDA.

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

The head cheese in charge of all the doctors, Dr. Patrizia Cavazzoni, who is the director of the FDA’s Center for Drug ...

"It is the FDA's role to ensure that drugs are safe and effective," said Dr. Patrizia Cavazzoni, director of the FDA's Center ...

“Based on our review of available data, and consistent with the advice of the advisory committee, we are taking this next step in the process,” said Patrizia Cavazzoni, M.D., director of the FDA’s ...

It will be co-led by Patrizia Cavazzoni, director of the FDA's Centre for Drugs Evaluation and Research (CDER), and Centre for Biologics Evaluation and Research (CBER) director Peter Marks.

It’s the second time in less than a month that retailer has recalled the medication; this time due to a potential foreign ...

“It is the FDA’s role to ensure that drugs are safe and effective,” said Patrizia Cavazzoni, MD, director of the agency’s Center for Drug Evaluation and Research (CDER). “Based on our ...